Trial reportClinical pharmacology in drug development2022
The Effect of Food on the Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan.
Trial report in Clinical pharmacology in drug development, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Clinical pharmacokinetics of potassium competitive acid blockers: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- The efficacy and safety of vonoprazan-amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis.European journal of medical research · 2023Pooled it
- Bioequivalence study of vonoprazan fumarate tablets in healthy Chinese subjects: a randomized, open-label, two-period crossover trial.Frontiers in pharmacology · 2026Trial
- Keverprazan, a novel potassium-competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects.Clinical and translational science · 2023Trial
- Vonoprazan pharmacokinetics and effects on gastric pH following administration to fed and fasted horses.Equine veterinary journal · 2026Article
- Potassium-competitive acid blockers and proton-pump inhibitors for the healing and maintenance of erosive esophagitis: a comprehensive and updated systematic review with network meta-analysis.Esophagus : official journal of the Japan Esophageal Society · 2026Review
- Vonoprazan vs Proton Pump Inhibitors for Gastroprotection in Anticoagulated Patients: A Real-World Cohort Study.Cureus · 2026Article
- Comparative renal safety: potassium-competitive acid blockers vs proton pump inhibitors.Clinical kidney journal · 2026Article
- Beyond acid suppression: the multifaceted role of proton pump inhibitors inFrontiers in microbiology · 2026Review
- Optimizing acid-related disease management: insights into potassium-competitive acid blockers and proton pump inhibitors.European journal of clinical pharmacology · 2025Review
- Research progress of potassium-competitive acid blockers in the treatment ofAnnals of medicine · 2025Review
- Vonoprazan: A Review in Erosive Esophagitis and Non-Erosive Gastro-Esophageal Reflux Disease.Drugs · 2025Review
- Advances in Gastroesophageal Reflux Disease Management: Exploring the Role of Potassium-Competitive Acid Blockers and Novel Therapies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Vonoprazan and proton pump inhibitors: Which is superior forWorld journal of gastroenterology · 2025Article
- Potassium-Competitive Acid Blockers and Proton Pump Inhibitors: The Dynamic Duo of Acid Blockers.Gastroenterology & hepatology · 2024Article
- Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments.Current gastroenterology reports · 2024Review
- Evaluating vonoprazan and tegoprazan for gastroesophageal reflux disease treatment in Chinese Healthcare: an EVIDEM framework analysis.BMC gastroenterology · 2024Article
- Review
- Predicting pharmacodynamic effects through early drug discovery with artificial intelligence-physiologically based pharmacokinetic (AI-PBPK) modelling.Frontiers in pharmacology · 2024Article
- Vonoprazan: A New Potassium-Competitive Acid Blocker.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Herein, we report a food-effect study of vonoprazan, an oral potassium-competitive acid blocker. In a phase 1, randomized, open-label, crossover study, healthy subjects received a single 20-mg dose of vonoprazan either following an overnight fast or 30 minutes after a high-fat breakfast. Plasma vonoprazan levels were determined at 0 hour and at 17 subsequent assessment points up to 48 hours after dosing. After a 5-day washout, subjects received a second 20-mg vonoprazan dose in the alternative fed/fasted state (identical process repeated). Twenty-four subjects completed the study. Vonoprazan exposure was not meaningfully affected by food. Geometric mean ratios for maximum concentration, area under the concentration-time curve from time 0 to 24 hours, and area under the plasma concentration-time curve extrapolated to infinity obtained under fed and fasting conditions were 1.05 (90% confidence interval, 0.98-1.12), 1.13 (1.09-1.18), and 1.15 (1.11-1.19), respectively. Four subjects experienced 6 adverse events that were all mild and considered unrelated to the study drug. Vonoprazan can be administered without regard to food intake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.